No, but after the first Personalized Prediction Profile service for a given patient, all subsequent Personalized Prediction Profile services for that patient are discounted.
All of our products are thoroughly validated in-house using clinical outcomes data and we have published multiple peer-reviewed papers demonstrating the efficacy of our predictions (Veterinary Sciences and Veterinary and Comparative Oncology). We have run over 12,000 tests on hematopoietic cells, and over 4,000 canine patients that have benefited from our services. We believe we have more data on canine lymphoma than any other company in the world.
At this time, we only offer commercial services to canine lymphoma patients. However, we are conducting research into feline lymphoma so if you would like to submit a sample please sign up here if you are interested in feline services.
We would suggest you submit another FNA and blood samples to us WHEN the patient's lymphoma relapses. Relapse of lymphoma means that the cancer develops a resistance to certain chemo drugs in use. When this happens, the relapsed cancer cells are usually different from the ones investigated in the naive status, which led to different drug response predictions to the tested drugs. Therefore, it would be better to get new tumor samples and find out what are the new preferred drugs and which of the used drugs still remain effective or became resistant for the relapsed lymphoma. However, the best scenario is to maintain clinical remission for as long a period of time so that you don’t have to order another service from us! If a second service is needed, we offer a 50% discount for returning patients.
Disinfect the skin with alcohol (70%) at the planned needle puncture site. Insert a 20-gauge needle (without syringe) into an enlarged lymph node and perform 15 - 20 aspirations using an aggressive “woodpecker style” technique. (Click to Read More)